FierceBiotech: A look back at biotech in 2009

[SOURCE: FIERCE BIOTECH] December 24, 2009 — 10:34am ET | By John Carroll

This year won't soon be forgotten in biotech circles. What started as a gut-wrenching financial disaster which quickly scuttled a slate of developers began to turn around last summer. By the end of the year some biotech companies were putting their toes into the public market waters to see whether they should dive in with an IPO. Other big outfits were able to report amazing progress. But it wasn't all good news. Slipping at the proof-of-concept stage can still be a near fatal experience and not every deal done in the last six months was completed at a premium.

READ MORE

1. Economic disaster followed by a revival in share prices

2. Dealmaking reaches fever pitch at year's end

3. Big Pharma upends its R&D empires

4. The genetic revolution takes aim at the pipeline

5. Congress prepares to deliver for biotechnology